2025 Q4 -tulosraportti
Äänite tulossa
1 päivä sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 min sittenCan someone with better insight explain: Reading in FA: «Pros are playing with the stock price in the stock rocket Circio, says stock trader Atle Sandvik Pedersen. – These are people who know what they are doing. They have had a good setup, and some have earned a lot of money, he says.» Is it Circio that knows what they are doing or stock speculators? And how can large players buy into a directed private placement at 10.8 only to see the money just disappear?! I don't understand this! Is it the same people who bought into the private placement who are now shorting with the same shares or how does this work. Hoping for sensible and informative contributions here. Asking out of ignorance. Hoping for a GREEN day :))
·17 min sittenWill it be green or red today, folks?
·Alle minuutti sittenGamle-Erik, also written Gammelerik, Gamle-Eirik and others, is one of the popular circumlocutions for the name of «the evil one» or the devil, in the Bible called Satan or Shaitan, «prince of darkness» and others, in folklore referred to as the fiend, hinmannen and others. According to folk belief, using the correct name for a demon, a threat or danger could act as an invocation of evil forces, and such names were therefore avoided or replaced with neutral words and more jocular euphemisms. Bad weather and predators were therefore also often referred to indirectly or with beautifying nicknames.
·21 min sittenFor those who haven't caught this, more info will follow in the comment section. Yes, there it is. A fresh PhD from Karolinska confirms the Circio case. This has gone under the radar, but today Jennifer Geara's doctoral thesis at Karolinska Institutet was published: "Modulating fibroblasts in hard-to-heal wounds and skin ageing: roles of circRNAs". By using terms such as "superior stability" (overlegen stabilitet) and "prolonged therapeutic effect" (langvarig terapeutisk effekt), Geara argues that circular RNA solves the biggest problems that have held back conventional RNA therapy. For those who want to read the technical details on how circRNA (e.g. CircMT-RNR2) controls fibroblasts, the entire thesis is available here: https://openarchive.ki.se/articles/thesis/Modulating_fibroblasts_in_hard-to-heal_wounds_and_skin_ageing_roles_of_circRNAs_and_dermal_injectables/31026202?file=63750444 One of the most exciting things was that Geara shows that we can now identify circRNA sequences that are highly specific to certain cell types or disease states. So instead of giving a medicine that affects the entire body, one can use circRNA technology (like the one Circio develops) to send a "coded message" that is only read and executed by the fibroblasts that are actually sick. Overall, this confirms the case to a great extent. Good luck, everyone!·18 min sitten1. Ning Xu Landén (Main supervisor) – "The circRNA Expert" Ning Xu Landén is one of the foremost experts in Europe on non-coding RNA (ncRNA), which includes both micro-RNA and circular RNA (circRNA). She leads the group where Jennifer Geara has done her work. Landén's research focuses specifically on how RNA molecules can be used to control wound healing and skin regeneration. That she is the main supervisor means that the dissertation is permeated with expertise on how circular molecules technically function in fibroblasts. 2. Yuval Rinkevich (Opponent) – The world leader in fibrosis That Yuval Rinkevich has been brought in as an opponent is a massive signal. He is one of the world's most recognized researchers on fibroblasts and scar formation. Rinkevich has made groundbreaking discoveries on how to stop scar formation (fibrosis) by manipulating specific fibroblast populations. When he acts as an opponent on a dissertation about circRNA, it confirms that the scientific community views circRNA as the next big tool to solve precisely the fibrosis puzzle – which is exactly what Circio is working on. 3. Guanglin Niu (Co-supervisor) – The specialist in ncRNA Guanglin Niu has published several articles together with the Landén group that deal precisely with how different types of RNA control skin cells. He has been central to the technical work of mapping molecular signaling pathways. 4. Liv Eidsmo and Pehr Sommar – The clinical bridge Liv Eidsmo is an expert on the skin's immune system. Her role is important because circRNA has a unique ability to modulate cells without triggering unnecessary inflammation (something Geara's dissertation also addresses). Pehr Sommar is a plastic surgeon. His involvement ensures that the research is relevant for real patients (e.g., after operations or major injuries). This is important for companies like Circio, because it shows that the technology has a practical, medical path to market, not just in theory.
·17 min sitten · MuokattuGood morning folks. Just want to remind you that as many who wish the stock well in here, just as many have short positions and try to make people panic by constantly writing negative things. Several admitted that yesterday, the case is just as strong as it always has been long-term.
·38 min sittenAnalysis: Circio (CRCI) – From crisis to fully funded biotech star? 🚀 I have reviewed the annual report for 2025 (published 15.04.26) and the latest events. Here are the most important points you should note: 1. Financial runway all the way to 2030! First things first: The financial risk is practically gone. After the share issues in February and April 2026, Circio has raised almost 320 million NOK. The company now states that they are funded all the way until 2030. This is extremely rare for a company at this stage on Oslo Børs. 2. The "Atlas ghost" is finally buried For everyone who held the share while Atlas Capital sold off: That facility is now permanently closed and all debt has been redeemed. The technical selling pressure that kept the price down last year is gone. 3. Validation from "Big Pharma" and prestigious ASGCT Circio now has a fully funded feasibility study with one of the 5 largest pharmaceutical companies in the world. Trigger: In May 2026, the company will have an oral presentation at the prestigious ASGCT conference in Boston. This is an enormous recognition of the circVec technology (generation 4.0). 4. Technological lead Their circRNA platform shows up to 50 times more powerful gene expression than regular mRNA. This makes them a very attractive partner for companies in gene and cell therapy. The collaboration with United Immunity (Japan) and Acuitas Therapeutics underscores this. Summary: Circio has gone from being a company with its "back against the wall" in 2025 to becoming one of the best-funded biotech bets on the stock exchange in 2026. With cash until 2030 and data-readouts pending, the relationship between risk and potential upside (risk/reward) looks very exciting at these levels. What do you think? Has the market woken up and seen that the risk of bankruptcy has been replaced by 4 years of peace to work? Disclaimer: This is not a buy recommendation. Always do your own analysis.
·28 min sittenGood summary.
·15 min sittenLol, why do you seem so grumpy? The most important thing is good information that benefits everyone.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Äänite tulossa
1 päivä sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 min sittenCan someone with better insight explain: Reading in FA: «Pros are playing with the stock price in the stock rocket Circio, says stock trader Atle Sandvik Pedersen. – These are people who know what they are doing. They have had a good setup, and some have earned a lot of money, he says.» Is it Circio that knows what they are doing or stock speculators? And how can large players buy into a directed private placement at 10.8 only to see the money just disappear?! I don't understand this! Is it the same people who bought into the private placement who are now shorting with the same shares or how does this work. Hoping for sensible and informative contributions here. Asking out of ignorance. Hoping for a GREEN day :))
- ·17 min sittenWill it be green or red today, folks?·Alle minuutti sittenGamle-Erik, also written Gammelerik, Gamle-Eirik and others, is one of the popular circumlocutions for the name of «the evil one» or the devil, in the Bible called Satan or Shaitan, «prince of darkness» and others, in folklore referred to as the fiend, hinmannen and others. According to folk belief, using the correct name for a demon, a threat or danger could act as an invocation of evil forces, and such names were therefore avoided or replaced with neutral words and more jocular euphemisms. Bad weather and predators were therefore also often referred to indirectly or with beautifying nicknames.
- ·21 min sittenFor those who haven't caught this, more info will follow in the comment section. Yes, there it is. A fresh PhD from Karolinska confirms the Circio case. This has gone under the radar, but today Jennifer Geara's doctoral thesis at Karolinska Institutet was published: "Modulating fibroblasts in hard-to-heal wounds and skin ageing: roles of circRNAs". By using terms such as "superior stability" (overlegen stabilitet) and "prolonged therapeutic effect" (langvarig terapeutisk effekt), Geara argues that circular RNA solves the biggest problems that have held back conventional RNA therapy. For those who want to read the technical details on how circRNA (e.g. CircMT-RNR2) controls fibroblasts, the entire thesis is available here: https://openarchive.ki.se/articles/thesis/Modulating_fibroblasts_in_hard-to-heal_wounds_and_skin_ageing_roles_of_circRNAs_and_dermal_injectables/31026202?file=63750444 One of the most exciting things was that Geara shows that we can now identify circRNA sequences that are highly specific to certain cell types or disease states. So instead of giving a medicine that affects the entire body, one can use circRNA technology (like the one Circio develops) to send a "coded message" that is only read and executed by the fibroblasts that are actually sick. Overall, this confirms the case to a great extent. Good luck, everyone!·18 min sitten1. Ning Xu Landén (Main supervisor) – "The circRNA Expert" Ning Xu Landén is one of the foremost experts in Europe on non-coding RNA (ncRNA), which includes both micro-RNA and circular RNA (circRNA). She leads the group where Jennifer Geara has done her work. Landén's research focuses specifically on how RNA molecules can be used to control wound healing and skin regeneration. That she is the main supervisor means that the dissertation is permeated with expertise on how circular molecules technically function in fibroblasts. 2. Yuval Rinkevich (Opponent) – The world leader in fibrosis That Yuval Rinkevich has been brought in as an opponent is a massive signal. He is one of the world's most recognized researchers on fibroblasts and scar formation. Rinkevich has made groundbreaking discoveries on how to stop scar formation (fibrosis) by manipulating specific fibroblast populations. When he acts as an opponent on a dissertation about circRNA, it confirms that the scientific community views circRNA as the next big tool to solve precisely the fibrosis puzzle – which is exactly what Circio is working on. 3. Guanglin Niu (Co-supervisor) – The specialist in ncRNA Guanglin Niu has published several articles together with the Landén group that deal precisely with how different types of RNA control skin cells. He has been central to the technical work of mapping molecular signaling pathways. 4. Liv Eidsmo and Pehr Sommar – The clinical bridge Liv Eidsmo is an expert on the skin's immune system. Her role is important because circRNA has a unique ability to modulate cells without triggering unnecessary inflammation (something Geara's dissertation also addresses). Pehr Sommar is a plastic surgeon. His involvement ensures that the research is relevant for real patients (e.g., after operations or major injuries). This is important for companies like Circio, because it shows that the technology has a practical, medical path to market, not just in theory.
- ·17 min sitten · MuokattuGood morning folks. Just want to remind you that as many who wish the stock well in here, just as many have short positions and try to make people panic by constantly writing negative things. Several admitted that yesterday, the case is just as strong as it always has been long-term.
- ·38 min sittenAnalysis: Circio (CRCI) – From crisis to fully funded biotech star? 🚀 I have reviewed the annual report for 2025 (published 15.04.26) and the latest events. Here are the most important points you should note: 1. Financial runway all the way to 2030! First things first: The financial risk is practically gone. After the share issues in February and April 2026, Circio has raised almost 320 million NOK. The company now states that they are funded all the way until 2030. This is extremely rare for a company at this stage on Oslo Børs. 2. The "Atlas ghost" is finally buried For everyone who held the share while Atlas Capital sold off: That facility is now permanently closed and all debt has been redeemed. The technical selling pressure that kept the price down last year is gone. 3. Validation from "Big Pharma" and prestigious ASGCT Circio now has a fully funded feasibility study with one of the 5 largest pharmaceutical companies in the world. Trigger: In May 2026, the company will have an oral presentation at the prestigious ASGCT conference in Boston. This is an enormous recognition of the circVec technology (generation 4.0). 4. Technological lead Their circRNA platform shows up to 50 times more powerful gene expression than regular mRNA. This makes them a very attractive partner for companies in gene and cell therapy. The collaboration with United Immunity (Japan) and Acuitas Therapeutics underscores this. Summary: Circio has gone from being a company with its "back against the wall" in 2025 to becoming one of the best-funded biotech bets on the stock exchange in 2026. With cash until 2030 and data-readouts pending, the relationship between risk and potential upside (risk/reward) looks very exciting at these levels. What do you think? Has the market woken up and seen that the risk of bankruptcy has been replaced by 4 years of peace to work? Disclaimer: This is not a buy recommendation. Always do your own analysis.·28 min sittenGood summary.·15 min sittenLol, why do you seem so grumpy? The most important thing is good information that benefits everyone.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Äänite tulossa
1 päivä sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 min sittenCan someone with better insight explain: Reading in FA: «Pros are playing with the stock price in the stock rocket Circio, says stock trader Atle Sandvik Pedersen. – These are people who know what they are doing. They have had a good setup, and some have earned a lot of money, he says.» Is it Circio that knows what they are doing or stock speculators? And how can large players buy into a directed private placement at 10.8 only to see the money just disappear?! I don't understand this! Is it the same people who bought into the private placement who are now shorting with the same shares or how does this work. Hoping for sensible and informative contributions here. Asking out of ignorance. Hoping for a GREEN day :))
- ·17 min sittenWill it be green or red today, folks?·Alle minuutti sittenGamle-Erik, also written Gammelerik, Gamle-Eirik and others, is one of the popular circumlocutions for the name of «the evil one» or the devil, in the Bible called Satan or Shaitan, «prince of darkness» and others, in folklore referred to as the fiend, hinmannen and others. According to folk belief, using the correct name for a demon, a threat or danger could act as an invocation of evil forces, and such names were therefore avoided or replaced with neutral words and more jocular euphemisms. Bad weather and predators were therefore also often referred to indirectly or with beautifying nicknames.
- ·21 min sittenFor those who haven't caught this, more info will follow in the comment section. Yes, there it is. A fresh PhD from Karolinska confirms the Circio case. This has gone under the radar, but today Jennifer Geara's doctoral thesis at Karolinska Institutet was published: "Modulating fibroblasts in hard-to-heal wounds and skin ageing: roles of circRNAs". By using terms such as "superior stability" (overlegen stabilitet) and "prolonged therapeutic effect" (langvarig terapeutisk effekt), Geara argues that circular RNA solves the biggest problems that have held back conventional RNA therapy. For those who want to read the technical details on how circRNA (e.g. CircMT-RNR2) controls fibroblasts, the entire thesis is available here: https://openarchive.ki.se/articles/thesis/Modulating_fibroblasts_in_hard-to-heal_wounds_and_skin_ageing_roles_of_circRNAs_and_dermal_injectables/31026202?file=63750444 One of the most exciting things was that Geara shows that we can now identify circRNA sequences that are highly specific to certain cell types or disease states. So instead of giving a medicine that affects the entire body, one can use circRNA technology (like the one Circio develops) to send a "coded message" that is only read and executed by the fibroblasts that are actually sick. Overall, this confirms the case to a great extent. Good luck, everyone!·18 min sitten1. Ning Xu Landén (Main supervisor) – "The circRNA Expert" Ning Xu Landén is one of the foremost experts in Europe on non-coding RNA (ncRNA), which includes both micro-RNA and circular RNA (circRNA). She leads the group where Jennifer Geara has done her work. Landén's research focuses specifically on how RNA molecules can be used to control wound healing and skin regeneration. That she is the main supervisor means that the dissertation is permeated with expertise on how circular molecules technically function in fibroblasts. 2. Yuval Rinkevich (Opponent) – The world leader in fibrosis That Yuval Rinkevich has been brought in as an opponent is a massive signal. He is one of the world's most recognized researchers on fibroblasts and scar formation. Rinkevich has made groundbreaking discoveries on how to stop scar formation (fibrosis) by manipulating specific fibroblast populations. When he acts as an opponent on a dissertation about circRNA, it confirms that the scientific community views circRNA as the next big tool to solve precisely the fibrosis puzzle – which is exactly what Circio is working on. 3. Guanglin Niu (Co-supervisor) – The specialist in ncRNA Guanglin Niu has published several articles together with the Landén group that deal precisely with how different types of RNA control skin cells. He has been central to the technical work of mapping molecular signaling pathways. 4. Liv Eidsmo and Pehr Sommar – The clinical bridge Liv Eidsmo is an expert on the skin's immune system. Her role is important because circRNA has a unique ability to modulate cells without triggering unnecessary inflammation (something Geara's dissertation also addresses). Pehr Sommar is a plastic surgeon. His involvement ensures that the research is relevant for real patients (e.g., after operations or major injuries). This is important for companies like Circio, because it shows that the technology has a practical, medical path to market, not just in theory.
- ·17 min sitten · MuokattuGood morning folks. Just want to remind you that as many who wish the stock well in here, just as many have short positions and try to make people panic by constantly writing negative things. Several admitted that yesterday, the case is just as strong as it always has been long-term.
- ·38 min sittenAnalysis: Circio (CRCI) – From crisis to fully funded biotech star? 🚀 I have reviewed the annual report for 2025 (published 15.04.26) and the latest events. Here are the most important points you should note: 1. Financial runway all the way to 2030! First things first: The financial risk is practically gone. After the share issues in February and April 2026, Circio has raised almost 320 million NOK. The company now states that they are funded all the way until 2030. This is extremely rare for a company at this stage on Oslo Børs. 2. The "Atlas ghost" is finally buried For everyone who held the share while Atlas Capital sold off: That facility is now permanently closed and all debt has been redeemed. The technical selling pressure that kept the price down last year is gone. 3. Validation from "Big Pharma" and prestigious ASGCT Circio now has a fully funded feasibility study with one of the 5 largest pharmaceutical companies in the world. Trigger: In May 2026, the company will have an oral presentation at the prestigious ASGCT conference in Boston. This is an enormous recognition of the circVec technology (generation 4.0). 4. Technological lead Their circRNA platform shows up to 50 times more powerful gene expression than regular mRNA. This makes them a very attractive partner for companies in gene and cell therapy. The collaboration with United Immunity (Japan) and Acuitas Therapeutics underscores this. Summary: Circio has gone from being a company with its "back against the wall" in 2025 to becoming one of the best-funded biotech bets on the stock exchange in 2026. With cash until 2030 and data-readouts pending, the relationship between risk and potential upside (risk/reward) looks very exciting at these levels. What do you think? Has the market woken up and seen that the risk of bankruptcy has been replaced by 4 years of peace to work? Disclaimer: This is not a buy recommendation. Always do your own analysis.·28 min sittenGood summary.·15 min sittenLol, why do you seem so grumpy? The most important thing is good information that benefits everyone.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt